ערך בספרים למניה: kairospharma.com (KAPA)

The lack of profitability and dependence on test results create significant risks for Kairos Pharma Ltd (KAPA). The development of targeted therapy serves as the primary growth driver. The book value per share helps assess financial strength, with 1.38 representing the current value of this metric. Kairos Pharma Ltd (KAPA) relies on cooperation with leading clinics to create innovative methods for combating tumor resistance.

Costly clinical trials and patent protection for oncological therapies define the asset structure of Kairos Pharma Ltd. The current value of 1.38 on the book value chart per ordinary share reflects net equity minus liabilities, measuring the company's real asset safety margin, where high capital protection may indicate both stability and the risk of low investment efficiency.